FLT3 and neoplasm: Additionally, investigator-engineered T cells overcome the clinical issue of antigen-negative tumor escape following adoptive cell therapy by secreting dendritic cell (DC) growth factor Fms-like tyrosine kinase 3 ligands (Flt3L) to stimulate the endogenous DCs and overcome tumor antigen heterogeneity (Figure 9)111.